Dr Elias Mai speaks to ecancer about choosing the optimal regimen in transplant-eligible NDMM.

Transplant eligibility is influenced by factors like patient fitness, comorbidities, and personal preferences.

Conditions such as heart disease and diabetes are key in determining treatment plans.

The urgency of treatment and disease characteristics also matter.

Eligible patients can consider combinations of Daratumumab with other drugs, and it's advised to conduct transplants right after induction therapy.

Emerging therapies like CAR T cells and bispecific antibodies may change the future landscape of transplant necessity.